Assessing the consistency of overall survival extrapolations in Swedish health technology assessment reports of oncology treatments using extended follow-up data.

Máté Szilcz^1,2, Olof Mogard³, Mattias Ekman⁴, Olof Lindgren⁵, Fredrik Nilsson⁶, Kasper Johannesen⁴, Emma Medin⁷

¹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

²Viti Science AB, Stockholm, Sweden.

³Parexel International, Zürich, Switzerland.

⁴AstraZeneca AB, Stockholm, Sweden.

⁵Takeda Pharma AB, Stockholm, Sweden.

⁶Pfizer AB, Stockholm, Sweden.

⁷Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden.

PubMed DOI

Abstract

BACKGROUND: Long-term overall survival (OS) extrapolations underpin cost-effectiveness appraisals, projecting survival beyond trial follow-up. We aimed to compare extrapolations presented in manufacturer submissions and appraisals published by the Swedish Dental and Pharmaceutical Benefits Agency (TLV) with extrapolations using OS data with longer follow-up available after the original appraisal.…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.